This disclosure relates to methods for identifying molecular arrangements useful in managing diseases or conditions. In certain embodiments, this disclosure relates to treating an immune regulated disease comprising administering to a subject in need thereof an effective amount of a grouped molecular arrangement comprising a specific binding agent to CD19, a specific binding agent to CD3, and IL-12. In certain embodiments, this disclosure relates to screening test compounds comprising providing a library of multifunctional binding specificities and contacting the library with cells to evaluate in vitro therapeutic potential.

A composition including an immunoconjugate and a chemotherapeutic agent. The immunoconjugate includes 1) one or more interleukins, and 2) an Fc domain consisting of a first Fc subunit and a second Fc subunit. The first Fc subunit associates with the second Fc subunit to form a dimer. The one or more interleukins are fused to the Fc domain and the chemotherapeutic agent includes a fluorouracil and/or an oxaliplatin.

The present invention relates to IL-7 variants, bifunctional molecules comprising it and their uses.

Provided herein are anti-FN-EIIIB nanobodies, conjugates thereof, and methods of using the nanobodies and conjugates thereof.

The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

The present invention relates to a dosage unit or regimen, recombinant protein for use, method or formulation of a recombinant protein comprising interleukin-12 (IL-12) and an antibody binding the extra-domain B (ED-B) of fibronectin, or a target binding fragment or derivative thereof.